San Antonio Breast Cancer Symposium 2025: Key Takeaways
The San Antonio Breast Cancer Symposium (SABCS) 2025, held December 9 to 12 in San Antonio, texas, brought clinicians, researchers, and oncology pharmacists together to highlight emerging data reshaping treatment paradigms across breast cancer subtypes. This year’s meeting emphasized breakthroughs in targeted therapies, refinements in treatment sequencing, safety considerations in supportive care, and the expanding role of pharmacists in precision oncology.
!San Antonio Riverwalk | Image credit: © Liang – stock.adobe.com
Beyond HER2-directed therapies, SABCS 2025 featured long-term findings from the MONALEESA trials evaluating ribociclib (Kisqali; Novartis), a CDK4/6 inhibitor, in hormone receptor-positive (HR+), HER2-negative advanced disease. Updated results demonstrated robust long-term disease control,with sustained progression-free survival benefits and manageable safety profiles,reinforcing the integral role of ribociclib in standard endocrine therapy regimens. These findings reaffirm CDK4/6 inhibitors as foundational in HR+ metastatic breast cancer and provide clinicians with confidence in long-term outcomes for patients.
2. DESTINY-Breast Trial Insights Inform Standard-of-Care Shifts
Emerging analyses from the DESTINY-Breast trial portfolio showcased how expanded use of trastuzumab deruxtecan (T-DXd, Enhertu; Daiichi Sankyo) across patient populations-including HER2-positive and HER2-low cohorts-may redefine standards of care. Integrating data from these studies, speakers highlighted improvements in both systemic control and patient outcomes, broadening the antibody drug conjugates’ (A